Citations

Clear

4610 citation(s) found for "Lu, Brian".

A Novel Radiomics Tool for Early Detection of Idiopathic Pulmonary Fibrosis
Rajagopalan, S., Do, Quan , Nwakama, Chibuzo, Herberts, Michelle , McCoy, John J., Holmes, David R. , Peikert, Tobias, Limper, Andrew H. , Rajagopalan, S., Bartholmai, Brian J. , McCoy, J.J., III, D.R. Holmes,

Mayo Clinic

C23. MACHINE LEARNED: AI-DRIVEN SOLUTIONS IN ILD AND LUNG TRANSPLANT | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A5103-A5103

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5103 Get It

Males With Cystic Fibrosis Have Larger Central Airway Luminal Areas Than Females
Guyer, R.E., Miller, Andrew , Dominelli, Paolo B. , Sanz, Javier, Welch, Brian T. , Miller, Alex J. , Roden, Richard , Joyner, Michael J. , Ramsook, Andrew H , Baker, Sarah E.

Mayo Clinic

C74. CYSTIC FIBROSIS AND NON-CF BRONCHIECTASIS | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6465-A6465

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6465 Get It

Interim Results From a Stepped Wedge Cluster Randomized Trial Using Artificial Intelligence to Increase Interpreter Use for Patients With Language Barriers
Strechen, Inna , Wilson, Patrick M. , Eltalhi, Targ, Piche, Kimberly, Tiong, Ing , Pickering, Brian W. , Herasevich, Svetlana , Barwise, Amelia

Mayo Clinic

C103. DISPARITIES AND SOCIAL DETERMINANTS OF HEALTH IN PULMONARY, CRITICAL CARE, AND SLEEP MEDICINE | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A6730-A6730

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a6730 Get It

Three‐Dimensional Imaging of the Patellofemoral Joint Improves Understanding of Trochlear Anatomy and Pathology and Planning of Realignment
Yu, Kristin E. , Venkadesan, Madhusudhan , Cooperman, Daniel R. , Beitler, Brian , Sieberer, Johannes , Fulkerson, John P. , Yu, Kristin, Sieberer, Johannes M , Schneble, Christopher A

Mayo Clinic

Arthroscopy | April 30, 2024 | Volume: 41 | Issue: 1 | Pages: 130-140

10.1016/j.arthro.2024.04.010 | PMID 38697330 Get It

Abstract Three‐dimensional (3D) modeling using digital or printed models provides a unique perspective that caters to cognitive spatial ability in a way that can add to our understanding and mental representations of human anatomy. This is particularly useful in the setting of trochlear dysplasia, where the morphology of the groove can exhibit substantial variability and complexity. Using 3D reformatted images and models, a pragmatic understanding of how morphology influences patellofemoral pathology can be gleaned. Further, this perspective facilitates cognition of what patellar tracking may look like after realignment procedures. Using 3D modeling, concepts such as patella alta, trochlear depth, lateralization of the patellar entry point, trochlear curvature, and the presence of a proximal trochlear spur can help afford a better understanding of how trochlear anatomy may influence tracking while also providing insight as to the ideal tracking path. The use of 3D has recently emerged as a useful tool in multiple surgical subspecialties, particularly in situations involving surgical planning or complex anatomy. Given the complexity and variation in trochlear morphology in patients with trochlear dysplasia who develop either patellar instability or focal overloading, 3D modeling is well‐suited to provide a perspective that can add to our understanding of trochlear dysplasia, and potentially even how we diagnose and treat it. Level of Evidence Level V, expert opinion.
The Morphologic Patella Entry Point Into the Proximal Trochlea Is More Lateral in Recurrent Dislocators Than Controls as Measured by Entry Point–Trochlear Groove Angle
Beitler, Brian , Sieberer, Johannes , Islam, Wasif , McDonald, Curtis , Yu, Kristin E. , Tommasini, Steven M. , Fulkerson, John P. , Yu, Kristin, Sieberer, Johannes M , Tommasini, Steven

Mayo Clinic

Arthroscopy | April 30, 2024 | Volume: 41 | Issue: 3 | Pages: 703-712

10.1016/j.arthro.2024.04.013 | PMID 38697328 Get It

Purpose To create a metric for evaluating the degree of laterality of the patella’s entry into the trochlea, the entry point–trochlear groove (EP‐TG) angle, and to evaluate if this laterality is associated with recurrent patella instability. Methods The time frame of the study was January 2020 to February 2023. The inclusion criteria were patients treated by the senior author (J.P.F.) (with the exception of 2 patients who were treated by another provider at the institution who was aware of the study) who have been diagnosed with recurrent atraumatic patellar dislocations. Controls without knee pathology were selected from the New Mexico Decedent Imaging Database (NMDID). Simpleware ScanIP was used to create 3‐dimensional (3D) models of the distal femurs from computed tomography scans. Anteroposterior images of these 3D models were uploaded to a custom EP‐TG angle measuring tool. Three measurers used the tool to measure the EP‐TG angle of the distal femurs. Results Twenty‐eight patients were included for the recurrent dislocator group. Twenty‐four decedents from the NMDID were selected for the control group, each with a left or right knee chosen randomly for measurement. A 1‐sided Mann‐Whitney U test, used to evaluate whether the recurrent dislocators had higher EP‐TG angle values, yielded a P value <.001, demonstrating a high level of significance. A Bayesian mixed‐effect model, used to determine how different the EP‐TG angles are between the 2 groups, gave a posterior predictive interval of [11.93°, 19.12°] for the EP‐TG angle shift of dislocators. The intraclass correlation coefficient was 0.648. Conclusions The morphologic entry point of the patella into the proximal trochlea is more lateral in recurrent patella dislocators than in controls. This increased laterality can be measured by the EP‐TG angle, which may be useful information for optimizing treatment of recurrent patella instability. Level of Evidence Level III, case control study.
Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma
Tine, Brian A. Van , Ingham, Matthew , Attia, Steven , Meyer, Christian F. , Baird, John D. , Brooks-Asplund, Esther M. , D'Silva, Dhiren, Kong, Ronald , Mwatha, Anthony, O’Keefe, Kylie, Weetall, Marla , Spiegel, Robert J. , Van Tine, Brian A , Ingham, Matthew A , Brooks-Asplund, Esther , Schwartz, Gary K , Meyer, Christian , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | April 29, 2024 | Volume: 42 | Issue: 20 | Pages: 2404-2414

10.1200/jco.23.01684 | PMID 38684039 Get It

PURPOSE This multicenter, single-arm, open-label, phase Ib study was designed to determine the recommended phase II dose (RP2D) and to evaluate the safety and preliminary efficacy of unesbulin plus dacarbazine (DTIC) in patients with advanced leiomyosarcoma (LMS). PATIENTS AND METHODS Adult subjects with locally advanced, unresectable or metastatic, relapsed or refractory LMS were treated with escalating doses of unesbulin orally twice per week in combination with DTIC 1,000 mg/m2 intravenously (IV) once every 21 days. The time-to-event continual reassessment method was used to determine the RP2D on the basis of dose-limiting toxicities (DLTs) assessed during the first two 21-day treatment cycles. All explored doses of unesbulin (200 mg up to 400 mg) were in combination with DTIC. An expansion cohort was enrolled to evaluate the safety and efficacy of unesbulin at the RP2D. RESULTS Unesbulin 300 mg administered orally twice per week in combination with DTIC 1,000 mg/m2 IV once every 21 days was identified as the RP2D. On the basis of data from 27 subjects who were deemed DLT-evaluable, toxicity was higher in the unesbulin 400 mg group, with three of four subjects (75%) experiencing DLTs versus one of four subjects (25%) in the 200 mg group and three of 19 subjects (15.8%) in the 300 mg group. The most commonly reported DLTs and treatment-related grade 3 and 4 adverse events were thrombocytopenia and neutropenia. At the RP2D, seven subjects who were efficacy evaluable achieved partial response for an objective response rate of 24.1%. CONCLUSION Unesbulin 300 mg twice per week plus DTIC 1,000 mg/m2 once every 21 days was identified as the RP2D, demonstrating a favorable benefit-risk profile in a heavily pretreated population of adults with advanced LMS.
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease
Wagemann, Olivia , Shi, Xinyu , Bittner, Tobias , Scelsi, Marzia A. , Farlow, Martin R. , Clifford, David B. , Santacruz, Anna , Aschenbrenner, Andrew J. , Hassenstab, Jason , Gordon, Brian A. , Coalier, Kelley A., Perrin, Richard J., Xiong, Chengjie , Li, Yan , Morris, John C. , Lah, James J., Berman, Sarah , Roberson, Erik D. , Dyck, Christopher H. van, Gauthier, Serge , Pariente, Jérémie , Mummery, Catherine J. , Day, Gregory S. , Ringman, John M. , Méndez, Patricio Chrem, Fox, Nick C. , Okhravi, Hamid , Chhatwal, Jasmeer P. , Xiong, Chengjie , Sims, John R. , Holdridge, Karen C. , Proctor, Nicholas K. , Yaari, R. , Andersen, Scott W. , Mancini, Michele , Unit, Dominantly Inherited Alzheimer Network–Trials, Daniels, Alisha , Courtney, Laura, Lu, Ruijin , Gremminger, Emily, Franklin, Erin , Jerome, Gina, Herries, Elizabeth, Baker, Bryce, Minton, Matthew, Goate, Alison , Picarello, Danielle M. , Hornbeck, Russ C. , Chen, Allison , Chen, Charles D., Jarman, Steve, Jackson, Kelley, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Sabaredzovic, Edita, Smith, Hunter , Scott, Jalen , Simmons, Ashlee, Rizzo, Jacqueline, Barthélemy, Nicolas R. , Xu, Jinbin , Ikonomović, Snežana, Nadkarni, Neelesh K. , Graff‐Radford, Neill R. , Huey, Edward D. , Salloway, Stephen , Bechara, Jacob , Ryan, Natalie S. , Laske, Christoph , Hofmann, Anna, Kuder-Buletta, Elke, Gräber‐Sultan, Susanne, Obermueller, Ulrike, Roedenbeck, Yvonne, Sánchez‐Valle, Raquel , Vázquez, Silvia , Leon, Yudy Milena, Ramírez, Laura, Seyfried, Nicholas T. , Fagan, Anne M. , Mori, Hiroshi , Gordon, Brian A , Roberson, Erik , Sánchez-Valle, Raquel , Day, Gregory S , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Aschenbrenner, Andrew J , Goate, Alison M , Berman, Sarah , Liu, Haiyan , Wang, Guoqiao , Supnet, Charlene , Benzinger, Tammie L.S. , Cruchaga, Carlos , Ibanez, Laura , Li, Yan, Dyck, Christopher H. van , Galasko, Douglas , Hsiung, Ging‐Yuek Robin , Brooks, William S. , George‐Hyslop, Peter St , Suzuki, Kazushi , Jucker, Mathias , Mancini, Michele, Llibre‐Guerra, Jorge J. , Bateman, Randall J. , McDade, Eric , Unit, Dominantly Inherited Alzheimer Network–Trials, Xu, Xiong, Stauber, Jennifer, Renton, Alan , Flores, Shaney , Joseph‐Mathurin, Nelly , McCullough, Austin , McKay, Nicole S. , Wáng, Qīng , Smith, Jennifer A. , Stout, Sarah Holtz , Karch, Celeste M. , Marsh, Jacob A. , Holtzman, David M. , Noble, James M. , Ikeuchi, Takeshi , Kasuga, Kensaku , Niimi, Yoshiki , Schofield, Peter R. , Martins, Ralph N. , Cash, David M. , Vöglein, Jonathan , Lee, Jae‐Hong , Roh, Jee Hoon , Rosa-Neto, Pedro , Allegri, Ricardo , Surace, Ezequiel , Lopera, Francisco Javier , Aguillon, David , Levey, Allan I. , Johnson, Erik C. B. , Masters, Colin L.

Mayo Clinic

JAMA Neurology | April 29, 2024 | Volume: 81 | Issue: 6 | Pages: 582

10.1001/jamaneurol.2024.0991 | PMID 38683602 Get It

Importance Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD). Objective To investigate longitudinal biomarker changes of synaptic dysfunction, neuroinflammation, and neurodegeneration in individuals with DIAD who are receiving antiamyloid treatment. Design, Setting, and Participants From 2012 to 2019, the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU-001) study, a double-blind, placebo-controlled, randomized clinical trial, investigated gantenerumab and solanezumab in DIAD. Carriers of gene variants were assigned 3:1 to either drug or placebo. The present analysis was conducted from April to June 2023. DIAN-TU-001 spans 25 study sites in 7 countries. Biofluids and neuroimaging from carriers of DIAD gene variants in the gantenerumab, solanezumab, and placebo groups were analyzed. Interventions In 2016, initial dosing of gantenerumab, 225 mg (subcutaneously every 4 weeks) was increased every 8 weeks up to 1200 mg. In 2017, initial dosing of solanezumab, 400 mg (intravenously every 4 weeks) was increased up to 1600 mg every 4 weeks. Main Outcomes and Measures Longitudinal changes in CSF levels of neurogranin, soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase 3–like 1 protein (YKL-40), glial fibrillary acidic protein (GFAP), neurofilament light protein (NfL), and plasma levels of GFAP and NfL. Results Of 236 eligible participants screened, 43 were excluded. A total of 142 participants (mean [SD] age, 44 [10] years; 72 female [51%]) were included in the study (gantenerumab, 52 [37%]; solanezumab, 50 [35%]; placebo, 40 [28%]). Relative to placebo, gantenerumab significantly reduced CSF neurogranin level at year 4 (mean [SD] β = −242.43 [48.04] pg/mL; P &amp;lt; .001); reduced plasma GFAP level at year 1 (mean [SD] β = −0.02 [0.01] ng/mL; P = .02), year 2 (mean [SD] β = −0.03 [0.01] ng/mL; P = .002), and year 4 (mean [SD] β = −0.06 [0.02] ng/mL; P &amp;lt; .001); and increased CSF sTREM2 level at year 2 (mean [SD] β = 1.12 [0.43] ng/mL; P = .01) and year 4 (mean [SD] β = 1.06 [0.52] ng/mL; P = .04). Solanezumab significantly increased CSF NfL (log) at year 4 (mean [SD] β = 0.14 [0.06]; P = .02). Correlation analysis for rates of change found stronger correlations between CSF markers and fluid markers with Pittsburgh compound B positron emission tomography for solanezumab and placebo. Conclusions and Relevance This randomized clinical trial supports the importance of fibrillar amyloid reduction in multiple AD-related processes of neuroinflammation and neurodegeneration in CSF and plasma in DIAD. Additional studies of antiaggregated amyloid therapies in sporadic AD and DIAD are needed to determine the utility of nonamyloid biomarkers in determining disease modification. Trial Registration ClinicalTrials.gov Identifier: NCT04623242
Survival outcomes in pediatric patients with metastatic Ewing sarcoma who achieve a rapid complete response of pulmonary metastases
Reiter, Audra J. , Huang, Lynn , Craig, Brian T. , Davidoff, Andrew M. , Coggins, Jordan , Smith, Jasmine , Aldrink, Jennifer H. , Bergus, Katherine , MacArthur, Taleen A. , Polites, Stephanie F. , Boehmer, Chloé , Brungardt, Joseph G. , Arkin, Cameron, Gourmel, Antoine , Piché, Nelson , Wallace, Marshall, Liang, Jiancong , Lovvorn, Harold N. , Petroze, Robin T. , Gillies, Gwendolyn S. , Marquart, John , Becktell, Kerri , Favela, Juan , Rich, Barrie S. , Glick, Richard D. , Seemann, Natashia M. , Davidson, Jacob , Wilson, Claire A. , Roach, Jonathan P. , Doyle, Kathleen , Coakley, Brian A. , Emengo, Pamela, Merola, Pamela R., Grant, Christa N. , Tirumani, Anuritha, Dasgupta, Roshni , Wallace, Marshall W. , Aldrink, Jennifer H , Bergus, Katherine C , MacArthur, Taleen A , Malek, Marcus M , Kastenberg, Zachary J , Piche, Nelson , Becktell, Kerri , Seemann, Natashia M , Tracy, Elisabeth T , Lautz, Timothy , Dasgupta, Roshni , Arkin, Cameron , Talbot, Lindsay J , Malek, Marcus M. , Rinehardt, Hannah , Kastenberg, Zachary J. , Wallace, Marshall, Le, Hau D. , Brown, Erin G. , Tracy, Elisabeth T. , Moya‐Mendez, Mary E. , Lautz, Timothy B.

Mayo Clinic

Pediatric Blood & Cancer | April 29, 2024 | Volume: 71 | Issue: 7 | Pages: No page available

10.1002/pbc.31026 | PMID 38679864 Get It

Abstract Purpose Our objectives were to compare overall survival (OS) and pulmonary relapse between patients with metastatic Ewing sarcoma (EWS) at diagnosis who achieve rapid complete response (RCR) and those with residual pulmonary nodules after induction chemotherapy (non‐RCR). Patients and methods This retrospective cohort study included children under 20 years with metastatic EWS treated from 2007 to 2020 at 19 institutions in the Pediatric Surgical Oncology Research Collaborative. Chi‐square tests were conducted for differences among groups. Kaplan–Meier curves were generated for OS and pulmonary relapse. Results Among 148 patients with metastatic EWS at diagnosis, 61 (41.2%) achieved RCR. Five‐year OS was 71.2% for patients who achieved RCR, and 50.2% for those without RCR ( p = .04), and in multivariable regression among patients with isolated pulmonary metastases, RCR (hazards ratio [HR] 0.42; 95% confidence interval [CI]: 0.17–0.99) and whole lung irradiation (WLI) (HR 0.35; 95% CI: 0.16–0.77) were associated with improved survival. Pulmonary relapse occurred in 57 (37%) patients, including 18 (29%) in the RCR and 36 (41%) in the non‐RCR groups ( p = .14). Five‐year pulmonary relapse rates did not significantly differ based on RCR (33.0%) versus non‐RCR (47.0%, p = .13), or WLI (38.8%) versus no WLI (46.0%, p = .32). Discussion Patients with EWS who had isolated pulmonary metastases at diagnosis had improved OS if they achieved RCR and received WLI, despite having no significant differences in rates of pulmonary relapse.
α‐Synuclein seed amplification assay detects Lewy body co‐pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden
Xiong, Chengjie , Quadalti, Corinne , Rossi, Marcello , Vöglein, Jonathan , Bernhardt, Alexander , Perrin, Richard J. , Preische, Oliver, Hofmann, Anna, Cairns, Nigel J. , Franklin, Erin , Chrem, Patricio, Berman, Sarah , Chhatwal, Jasmeer P. , Daniels, Alisha , Day, Gregory S. , Ryan, Natalie S. , Goate, Alison , Gordon, Brian A. , Huey, Edward D. , Masters, Colin L. , Morris, John C. , Noble, James M. , Roh, Jee Hoon , Frosch, Matthew P. , Sánchez‐Valle, Raquel , Supnet, Charlene , Network, Dominantly Inherited Alzheimer, Xiong, Chengjie , Parchi, Piero , Gordon, Brian A , Sánchez-Valle, Raquel , Day, Gregory S , Masters, Colin L , Vöglein, Jonathan , Morris, John C , Roh, Jee Hoon , Goate, Alison M , Supnet-Bell, Charlene , Berman, Sarah , Noble, James M , Baiardi, Simone , Iranzo, Alex , Jucker, Mathias , Höglinger, Günter U. , Cruchaga, Carlos , Ibanez, Laura , Karch, Celeste M. , Lee, Jae‐Hong , Llibre‐Guerra, Jorge J. , Lopera, Francisco Javier , Renton, Alan , Keene, C. Dirk , McLean, Catriona , Schofield, Peter R. , Xiong, Chengjie , Giese, Armin , Hansson, Oskar , Bateman, Randall J. , McDade, Eric , Network, Dominantly Inherited Alzheimer

Mayo Clinic

Alzheimer's & Dementia | April 26, 2024 | Volume: 20 | Issue: 6 | Pages: 4351-4365

10.1002/alz.13818 | PMID 38666355 Get It

AbstractINTRODUCTIONAmyloid beta and tau pathology are the hallmarks of sporadic Alzheimer's disease (AD) and autosomal dominant AD (ADAD). However, Lewy body pathology (LBP) is found in ≈ 50% of AD and ADAD brains.METHODSUsing an α‐synuclein seed amplification assay (SAA) in cerebrospinal fluid (CSF) from asymptomatic (n = 26) and symptomatic (n = 27) ADAD mutation carriers, including 12 with known neuropathology, we investigated the timing of occurrence and prevalence of SAA positive reactivity in ADAD in vivo.RESULTSNo asymptomatic participant and only 11% (3/27) of the symptomatic patients tested SAA positive. Neuropathology revealed LBP in 10/12 cases, primarily affecting the amygdala or the olfactory areas. In the latter group, only the individual with diffuse LBP reaching the neocortex showed α‐synuclein seeding activity in CSF in vivo.DISCUSSIONResults suggest that in ADAD LBP occurs later than AD pathology and often as amygdala‐ or olfactory‐predominant LBP, for which CSF α‐synuclein SAA has low sensitivity.Highlights Cerebrospinal fluid (CSF) real‐time quaking‐induced conversion (RT‐QuIC) detects misfolded α‐synuclein in ≈ 10% of symptomatic autosomal dominant Alzheimer's disease (ADAD) patients. CSF RT‐QuIC does not detect α‐synuclein seeding activity in asymptomatic mutation carriers. Lewy body pathology (LBP) in ADAD mainly occurs as olfactory only or amygdala‐predominant variants. LBP develops late in the disease course in ADAD. CSF α‐synuclein RT‐QuIC has low sensitivity for focal, low‐burden LBP.
Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn’s Disease
Khanna, Reena , Feagan, Brian G. , Stitt, Larry, McDonald, John WD, Bressler, Brian , Panaccione, Remo , Shackelton, Lisa M. , VanViegen, Tanja, Jairath, Vipul , D’Haens, Geert , Sandborn, William J. , Jairath, Vipul , Jairath, Vipul , Panaccione, Remo , D'Haens, G , Jairath, V , Jairath, V , Jairath, Vipul , Zou, Guangyong , Loftus, Edward V. , Daperno, Marco

Mayo Clinic

Inflammatory Bowel Diseases | April 25, 2024 | Volume: 31 | Issue: 3 | Pages: 706-715

10.1093/ibd/izae089 | PMID 38661492 Get It

Abstract Background Regulatory guidance for Crohn’s disease trials recommends coprimary efficacy end points that evaluate both symptoms and mucosal inflammation. We aimed to characterize the operating properties of commonly used disease activity assessments alone and in combination. Methods Endoscopic and clinical data were available for 129 participants from the Study of Biologic and Immunomodulator Naïve Patients in Crohn’s Disease trial. Readers scored the Simple Endoscopic Score for Crohn’s Disease and the Crohn’s Disease Endoscopic Index of Severity using standardized conventions. Index reliability was determined using intraclass correlation coefficients. Index responsiveness was assessed using standardized effect sizes based upon treatment assignment. Outcomes were evaluated for optimal sensitivity to treatment effect. Results Substantial inter-rater reliability was observed when the Simple Endoscopic Score for Crohn’s Disease and Crohn’s Disease Endoscopic Index of Severity were used as continuous measures (intraclass correlation coefficient, 0.64; 95% confidence interval [CI], 0.50-0.73; and 0.62 95% CI, 0.36-0.77) compared with moderate reliability when dichotomized (0.46; 95% CI, 0.26-0.65; and 0.51; 95% CI, 0.00-0.78). The Simple Endoscopic Score for Crohn’s Disease, Crohn’s Disease Endoscopic Index of Severity, patient-reported outcome-2, and Crohn’s Disease Activity Index were similarly responsive (standardized effect size, 0.43, 95% CI, 0.05-0.81; 0.38, 95% CI, 0.0-0.76; 0.53, 95% CI, 0.15-0.91). A composite outcome of Crohn’s Disease Activity Index score &lt;150 and Crohn’s Disease Endoscopic Index of Severity score &lt;6 was most sensitive to treatment effect (28.9%; 95% CI, 11.0%-46.8%; P = .003). Conclusion Endoscopic indices were more reliable as continuous measures. Composite outcomes including endoscopy improved sensitivity to treatment effect.